AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
Live video webcast on Monday, June 17th at 1:00 PM ET
6月17日週一下午1點(東部時間)直播視頻
OCALA, Fla., June 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024 at 1:00 PM ET.
佛羅里達州奧卡拉, 2024年6月10日 — AIM Immunotech股份有限公司。(紐約證券交易所美國:AIM)(“AIM”或“公司”)今天宣佈Thomas K. Equels,MS JD,首席執行官AIM將於2024年6月5日星期三參加虛擬投資者午餐會客戶系列活動虛擬投資者路演會議將於2024年6月17日星期一美國東部時間下午1:00舉行。
As part of the event, Mr. Equels will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.
作爲活動的一部分,Equels先生將提供"電梯演講",並概述公司即將到來的重要事件。此外,投資者和有興趣的人在活動期間將有機會實時提交問題。參與公司將在允許的時間內儘可能回答儘可能多的問題。
A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
機器人演示的網絡直播視頻將在公司網站(aimimmuno.com)的“活動”頁面上提供。演示的網絡直播視頻將在現場演示後兩小時提供,並可訪問90天。有關AIM Immunotech股份有限公司的信息,請訪問aimimmuno.com並與公司聯繫。(aimimmuno.com)。演講的網絡直播視頻將在現場演示後兩小時提供,並可訪問90天。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫藥品公司,專注於研究和開發治療多種癌症、免疫性疾病和病毒性疾病(包括COVID-19)的治療藥物。該公司的主要產品是一種名爲Ampligen(吡咯烷寡核苷酸)的首創調節免疫器官的藥物,具有廣泛的臨床試驗、覆蓋全球重要癌症、病毒性疾病和免疫系統疾病的廣譜活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM免疫技術公司是一家專注於研究和開發治療多種癌症、免疫系統疾病和病毒性疾病(包括COVID-19)藥物的免疫藥物公司。該公司的主要產品是一種名爲Ampligen的一類調節免疫反應的創新藥物。Ampligen(Rintatolimod)是一種dsRNA和高選擇性TLR3激動劑免疫調節劑,具有廣譜的臨床試驗活性,可用於全球重要癌症、病毒性疾病和免疫系統紊亂的治療。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
有關更多信息,請訪問 aimimmuno.com並聯系該公司。X, LinkedIn和Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
投資者聯繫人:JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com。
譯文內容由第三人軟體翻譯。